The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
General Medicine
Reference18 articles.
1. Social, economic, and health utility considerations in the treatment of overactive bladder;Sacco;Open Access J Urol,2010
2. Urodynamic efficacy and safety of mirabegron add-on treatment with tamsulosin for Japanese male patients with overactive bladder;Wada;Low Urin Tract Symptoms,2016
3. Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics;Nishizawa;Low Urin Tract Symptoms,2011
4. Clinical efficacy and safety of imidafenacin as add-on treatment for persistent overactive bladder symptoms despite alpha-blocker treatment in patients with BPH: the ADDITION study;Takeda;Urology,2013
5. Tamsulosin combined with solifenacin versus tamsulosin monotherapy for male lower urinary tract symptoms: a meta-analysis;Gong;Curr Med Res Opin,2015
Cited by 22 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Safety and efficacy of an α1‐blocker plus mirabegron compared with an α1‐blocker plus antimuscarinic in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia and overactive bladder: a systematic review and network meta‐analysis;Neurourology and Urodynamics;2024-01-30
2. Pharmacological Approaches in Managing Symptomatic Relief of Benign Prostatic Hyperplasia: A Comprehensive Review;Cureus;2023-12-30
3. Risks and side effects in the medical management of benign prostatic hyperplasia;Prostate International;2023-12
4. Comparison of add-on medications for persistent storage symptoms after α-blocker treatment in BPH patients – a network meta-analysis;BMC Urology;2023-10-03
5. Reply to Eleonora Rosato, Riccardo Lombardo, Vincenzo Li Marzi, Enrico Finazzi Agrò, Cosimo De Nunzio, and Simone Albisinni’s Letter to the Editor re: Rano Matta, Refik Saskin, Sarah Neu, et al. Predicting Mirabegron Treatment Response in Patients with Overactive Bladder: A Post Hoc Analysis of Data from Clinical Trials. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.04.001;European Urology Focus;2023-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3